A Study of Sacituzumab Govitecan in People With Mesothelioma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
Eligibility criteria
Qualifiers
Patient, or legally authorized representative (LAR), willing and able to provide written informed consent for the trial
Patient age ≥ 18 at time of consent
Pathologically confirmed diffuse pleural mesothelioma
Must have received at least one prior systemic therapy (platinum/pemetrexed, immunotherapy or a combination thereof)
Disqualifiers
Currently participating in another study and receiving another study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment
Prior hypersensitivity to irinotecan or any components of sacituzumab govitecan-hziy
Prior cytotoxic/immunologic systemic therapy within 3 weeks prior to study Day 1 or has not recovered (i.e., CTCAE v5 ≥ Grade 1 at baseline; from clinically significant adverse events due to a previously administered agent (excluding Grade 2 neuropathy)
Known psychiatric or substance abuse disorders that would interfere with the requirements of the trial within the opinion of the investigator
Trial design
Treatments tested in this trial
- Sacituzumab govitecan-hziy
Treatment groups
33 Participants
are divided into 1 treatment groupSponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Gilead Sciences
Collaborator
Source ClinicalTrials.gov